Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Summary of published data for chemical ablation in patients with brachial cleft cysts^{^a}
Study Year No. of Patients Sclerosing Agent Mean Treatment Sessions (No.) Complete Response Partial (≥50%) Response Partial (<50%) Response No Response Complications
Fukumoto et al² 1994 3 Ethanol 1.0 100.0% (3/3) – – None
Roh et al⁵ 2006 12 OK-432 2.3 58.3% (7/12) 25.0% (3/12) 16.7% (2/12) Fever
Kim et al⁴ 2009 23 OK-432 1.7 60.8% (14/23) 13.0% (3/23) 8.7% (2/23) 17.4% (4/23) Fever, local pain
Ohta et al⁶ 2010 12 OK-432 2.9 50.0% (6/12) 16.7% (2/12) 8.3% (1/12) 25.0% (3/12) Fever
↵a Numbers in parentheses are the numbers of patients among all those included in the study.

Study	Year	No. of Patients	Sclerosing Agent	Mean Treatment Sessions (No.)	Complete Response	Partial (≥50%) Response	Partial (<50%) Response	No Response	Complications
Fukumoto et al²	1994	3	Ethanol	1.0	100.0% (3/3)	–		–	None
Roh et al⁵	2006	12	OK-432	2.3	58.3% (7/12)	25.0% (3/12)		16.7% (2/12)	Fever
Kim et al⁴	2009	23	OK-432	1.7	60.8% (14/23)	13.0% (3/23)	8.7% (2/23)	17.4% (4/23)	Fever, local pain
Ohta et al⁶	2010	12	OK-432	2.9	50.0% (6/12)	16.7% (2/12)	8.3% (1/12)	25.0% (3/12)	Fever